Skip to main content

Summary of TACTIC-R protocol published by BMC

A structured summary of a study protocol for a randomised controlled trial of Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients - mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 – Repurposed Drugs (TACTIC-R) has been published in the BioMed Central Journal.

TACTIC-RThe TACTIC programme emerged from the hypothesis that immunomodulation would be likely to reduce the severity of COVID-19-related disease – a model supported by results from the RECOVERY trial indicating that a corticosteroid, dexamethasone, reduces mortality in patients with severe disease. TACTIC has been designed to assess selected medications which modify aspects of the immune response. These medications have been chosen by a consortium of clinicians and clinician-scientists with expertise in the treatment of immune-mediated disease and it is hoped that they will further reduce morbidity and mortality from COVID-19-related disease.

The TACTIC-R trial, using licensed drugs ‘Repurposed’ for the treatment of COVID-19-related disease, launched in Cambridge on 7th May 2020. The trial has three arms in a parallel-group, randomised design.

The treatments currently being tested are:

  • Baricitinib – a drug routinely used to treat rheumatoid arthritis, which reduces soluble signals in the immune system called cytokines. It is hypothesised that this will reduce the damaging inflammatory drive in COVID-19-related disease.

  • Ravulizumab – a drug used to treat a form of anaemia caused by the person’s immune system; this blocks activation of a cascade of soluble molecules which amplify inflammatory signals and, ultimately, destroy cells.

  • Standard of Care – itself evolving as data emerge from other clinical trials.

For more information visit: CamCovidTrials

Published July 8, 2020

Latest from CCTU

Covid-19 treatment trial for kidney patients goes national

An Addenbrooke’s trial is rolling out to hospitals across the UK to see if a drug used to treat tapeworm can give high-risk kidney patients extra protection…

The PROTECT-V trial investigating UNIONs COVID-19 candidate receives Urgent Public Health Prioritization from the UK government

UNION therapeutics A/S (UNION) today announced that the National Institute for Health Research (NIHR) in the UK has granted Urgent Public Health (UPH)…

Trials to find preventative COVID-19 treatments for most vulnerable to launch in UK

Two new clinical trials to develop treatments to prevent people catching (coronavirus) COVID-19 are to launch in the UK.

All news